ArticleScientific reports2025
ADIPOQ regulates lipid metabolism by activating AMPK/CPT-1 pathway to attenuate the proliferation of psoriasis lesions.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Psoriasis is an immune-mediated chronic inflammatory skin disease, with over 100 million people affected worldwide. This disease is accompanied by significant lipid metabolism disorders, affecting the circulatory system and skin tissue. This study found that patients with psoriasis have abnormal lipid metabolism, among which the levels of long-chain fatty acids (LCFAs) and mitochondrial pyruvate carriers (MPC) in mesenchymal stem cells (MSCs) are significantly lower than those in healthy controls. It is worth noting that the key regulatory factor of lipid metabolism, ADIPOQ (adiponectin), is down-regulated in psoriasis and functions dependent on LCFAs oxidation and carnitine palmitoyltransferase 1 (CPT1) under conditions of high substrate demand. Mechanically, ADIPOQ significantly inhibits the proliferation of normal human keratinocytes (NHEKs) by activating the p-AMPK/AMPK (AMP-activated protein kinase) signal and enhancing the activity of CPT1 enzyme. In the imQ-induced psoriasis-like mouse model, exogenous ADIPOQ intervention can improve epidermal thickening and down-regulate the expression of inflammatory factors through the AMPK-CPT1 pathway. In conclusion, this study reveals that ADIPOQ treatment can inhibit the proliferation of NHEKs by reshaping lipid metabolism, thereby delaying the progression of psoriasis. Targeting this metabolic pathway may provide a new strategy for clinical intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.